Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Receipts on Account of Shares [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Common Stock Option [Member] Shares Issuable Upon Conversion of Warrants [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Note Purchase Agreement [Member] Debt Instrument [Axis] Promissory Note [Member] September 2025 Note [Member] Note Exchange Agreement [Member] Two Exchange Agreements [Member] Title and Position [Axis] Note Investor [Member] Securities Purchase Agreement [Member] Prefunded Warrants [Member] Common Warrants [Member] Sales Agreement [Member] Statistical Measurement [Axis] Maximum [Member] Series A Warrants [Member] Series B Warrants [Member] Warrant [Member] Legal Entity of Counterparty, Type [Axis] Israeli Innovation Authority [Member] Minimum [Member] Legal Entity [Axis] Intellectual Property Purchase Agreement [Member] Business Combination [Axis] Lokahi Therapeutics Inc [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Preferred Stock [Member] Merger Agreement [Member] Bridge Notes [Member] Purchase Agreement and Security Agreement [Member] Common Stock Purchase Agreement [Member] White Lion Capital LLC [Member] Exchange Agreement [Member] Warrant Shares [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement of Financial Position [Abstract] Current Assets Cash and cash equivalents Other current assets Total current assets Operating lease right-of-use asset, net Property and equipment, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Current Liabilities Accounts payable Operating lease liability, current Promissory notes Other current liabilities Total current liabilities Non-Current Liabilities Derivative financial liabilities Operating lease liability, non-current Loans from stockholders Total liabilities Commitments and contingent liabilities (Note 4) Stockholders’ Equity (Deficit) Common Stock of $0.001 par value 250,000,000 shares authorized as of June 30, 2026 and as of December 31, 2025; 6,259,279 and 910,688 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Additional paid-in capital Receipts on account of shares Accumulated other comprehensive income Accumulated deficit Total stockholders’ equity (deficit) TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses Research and development expenses General and administrative expenses Total operating expenses Operating loss Other (income) expense Change in fair value of derivative Liabilities Other (income) expense, net Finance income, net Net Loss Other comprehensive income: Foreign currency translation adjustment Comprehensive loss for the period Basic net loss per common stock Diluted net loss per common stock Weighted average number of common stock used in computing basic loss per common stock Weighted average number of common stock used in computing diluted loss per common stock Statement [Table] Statement [Line Items] Balance Balance, shares Loss for the period Other comprehensive income Stock-based compensation Issuance of common stock for debt Issuance of common stock for debt, shares Exercise of warrants into common stock Exercise of warrants into common stock, shares Issuance of common stock upon exercise of pre-funded warrants Issuance of common stock upon exercise of pre-funded warrants, shares Issuance of common stock upon completion of ELOC financing, net of offering expenses Issuance of common stock upon completion of ELOC financing, net of offering expenses, shares Issuance of common stock upon the completion of public offerings, net of offering expenses Issuance of common stock upon the completion of public offerings, net of offering expenses, shares Stock split adjustment Stock split adjustment, shares Cashless exchange of warrants into common shares Issuance of common stock upon the completion of public offerings, net of offering expenses of $539, shares Balance Balance, shares Statement of Stockholders' Equity [Abstract] Offering expenses Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock-based compensation Amortization of original issue discount related to promissory note Loss on extinguishment of debt Change in fair value of derivative liability Amortization of debt discount and interest expense related to promissory notes Loss on warrant repurchase Changes in assets and liabilities: Other current assets Accounts payable Other current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from exercise of pre-funded warrants Net proceeds from ELOC financing Payment of promissory note Net proceeds from underwritten U.S. public offerings Series A warrant repurchase Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents, and restricted cash Change in cash and cash equivalents, and restricted cash Cash and cash equivalents, and restricted cash at beginning of the period Cash and cash equivalents, and restricted cash, end of period Supplemental disclosure of cash flow activities: (a) Net cash paid during the quarter for: Interest Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Transactions Significant Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingent Liabilities Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Functional Currency Principles of Consolidation Cash and Cash Equivalents and Restricted Cash Property and Equipment, Net Software development costs Convertible Promissory Notes Warrants Fair Value of Financial Instruments Basic and Diluted Loss Per Share Stock-Based Compensation Segment Reporting Schedule of Derivative Liabilities Measured At Fair Value Schedule of Anti Dilutive Securities Accumulated deficit Proceeds from public offerings and debt issuances Reverse stock split Balance - November 14, 2024 - Warrant issuance date Fair value adjustments - Derivative financial liability Warrant liability, ending balance Cashless exchange of warrants into Common Stock Series A Warrant repurchase Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Restricted cash Change in fair value of derivative liabilities Change in fair value of derivative liabilities Antidilutive securities SignificantTransactionsTable [Table] SignificantTransactionsLineItems [Line Items] Principal amount Purchase price Original issue discount to interest expense Unamortized discount Notes payable carrying amount Issuance of common stock upon the completion of public offerings, net of offering expenses Debt description Repayment of principal outstanding Number of shares exchanged for debt Number of shares exchanged for debt, shares Loss on extinguishment of debt Common stock issued upon exercise of warrants Common stock, shares Offering price Issuance of common stock upon completion of public offering, net of offering expenses, shares Share price Warrant exercise price Value of shares issued exercise Number of shares issued Net proceeds Warrants exercised Warrants term Warrants exercise price Price volatility Risk free interest rate Share price Change in fair value of warrants Fair value of the warrants exercised Fair value of derivative liability Loss Contingencies [Table] Loss Contingencies [Line Items] Contingent consideration liability Royalty percentage maximum Number of common shares issued Commission as a percentage of aggregate sales price Description related to IP agreement Subsequent Event [Table] Subsequent Event [Line Items] Description of shares issued and outstanding Number of shares issued Number of shares not yet been issued Minimum price Aggregate amount of private placement Gross aggregate amount of private placement Subsidiary contribution, description Percentage of outstanding equity of the Acquiror Gross proceeds Description of registration rights Description of bridge stock holder approval Percentage of original issue discount rate Interest rate Description of maturity Debt conversion description Exercisable warrants term Issuance of exercise Original issue discount Number of shares, value Percentage of shares outstanding Percentage of beneficial ownership limitation Commitment fee amount Commitment warrant Liquidated damages Additional liquidated damages Sale of stock shares Net proceeds Note exchange value Number of shares exchanged Warrants to purchase shares Shares issued price per share Aggregate gross proceeds Receipts on account of shares. Finance expense income net. Receipts on Account of Shares [Member] Stock issued during period value exercise of prefunded warrants. Loss on extinguishment of debt. Exercise of warrants into common stock. Issuance of common stock for debt. Exchange of warrants into common stock. Issuance of common stock for debt, shares. Exercise of warrants into common stock, shares Exercise of prefunded warrants, shares Stock split adjustment. Stock split adjustment, shares Exchange of warrants into common stock, shares. Amortization of original issue discount related to promissory note. Proceeds received from underwritten public offering. Loss on warrant repurchase. Proceeds from public offerings and debt issuances. Minimum bid price. Minimum stockholders equity. Functional Currency [Policy Text Block] Convertible Promissory Notes [Policy Text Block] Significant Transactions [Text Block] Note Purchase Agreement [Member] Promissory Note [Member] September 2025 Note [Member] Note Exchange Agreement [Member] Two Exchange Agreements [Member] Note Investor [Member] Securities Purchase Agreement [Member] Prefunded Warrants [Member] Common Warrants [Member] Sales Agreement [Member] Series A Warrants [Member] Series B Warrants [Member] Fair value of the warrants exercised. Israeli Innovation Authority [Member] Royalty percentage. Intellectual Property Purchase Agreement [Member] Aggregate sales price of units percentage. Description of shares issued and outstanding. Lokahi Therapeutics Inc [Member] Merger Agreement [Member] Gross proceeds from issuance of private placement. Description of subsidiary contribution. Percentage of outstanding equity of acquiror. Description of registration rights. Description of bridge stock holder approval. Bridge Notes [Member] Common Stock Purchase Agreement [Member] White Lion Capital LLC [Member] Percentage of shares outstanding. Percentage of beneficial ownership limitation. Commitment fee amount. Loss contingency additional damages sought value. Exchange Agreement [Member] Common Stock Option [Member] Shares Issuable Upon Conversion of Warrants [Member] Cashless exchange of warrants into common shares. Number of shares not yet been issued. Purchase Agreement and Security Agreement [Member] Number of shares exchanged. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Derivative, Gain (Loss) on Derivative, Net Other Nonoperating Income (Expense) FinanceExpenseIncomeNet Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Current Liabilities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Property, Plant, and Equipment Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Payments for Repurchase of Warrants Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Significant Transactions [Text Block]